---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-255185"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:00:00.520411+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma licenses neffy to ALK for $145M upfront; up to $320M milestones

## Summary
- Upfront $145M from ALK; regulatory/commercial milestones up to $20M and sales milestones up to $300M.
- Exclusive license for epinephrine nasal spray (neffy) outside US, Japan, China, Australia, New Zealand for all human uses.
- Tiered royalties in mid-to-high teens on net sales; ARS supplies product for first 5 years under supply agreement.
- ALK must use commercially reasonable efforts for regulatory approval and commercialization; ARS may terminate if ALK sells competing non-injectable epinephrine in US.
- Deal covers anaphylaxis and Type I allergic reactions; parties may agree on future indications.

## SEC filing metadata
- accession: 0001193125-24-255185
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312524255185/0001193125-24-255185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312524255185/d810986d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-255185
- JSON: https://secwatch.observer/filing/0001193125-24-255185.json
- Plain text: https://secwatch.observer/filing/0001193125-24-255185.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.